Volker Kunzmann - Concepedia

Author

Volker Kunzmann

Also Known As

Andreas Hochhaus, Kunzmann V, Kunzmann, V., Kunzmann, Volker, M. Fein, Monika Warmuth-Metz, V Kunzmann, V. Kunzmann, Volker Kunzmann, Volker Kunzmann (Würzburg)

237

Publications

11.1K

Citations

H-Index

Concepts

All Affiliations

University of Würzburg Universitätsklinikum Würzburg Heidelberg University Goethe University Frankfurt Charité - Universitätsmedizin Berlin

About

Volker Kunzmann is an author at University of Würzburg specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	39	4.8K
2	Health Sciences	12	12	1.3K
3	Natural Sciences	2	2	329
4	Public Health	1	1	25
5	Social Sciences	1	1	329

Volker Kunzmann

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial David Goldstein, Robert H. El-Maraghi, Pascal Hammel, JNCI Journal of the National Cancer Institute	2015	656
Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Volker Kunzmann, Eva Bauer, Juliane Feurle, Blood	2000	625
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
γδ T cells for immune therapy of patients with lymphoid malignancies Martin Wilhelm, Volker Kunzmann, Susanne Eckstein, Blood	2003	528
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Christoph Röllig, Hubert Serve, Andreas Hüttmann, The Lancet Oncology Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology	2015	395
The Berlin brain-computer interface: EEG-based communication without subject training Benjamin Blankertz, Guido Dornhege, Matthias Krauledat, IEEE Transactions on Neural Systems and Rehabilitation Engineering Bci ControlHealthy SubjectsMotor SkillBerlin Brain-computer InterfaceMotor Control	2006	329
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial Hubert Serve, Utz Krug, Ruth Wagner, Journal of Clinical Oncology	2013	309
Activation of Vγ9Vδ2 T Cells by NKG2D Bladimiro Rincón‐Orozco, Volker Kunzmann, Philine Wrobel, The Journal of Immunology Vγ9vδ2 T CellsCancer ImmunosurveillanceHuman Nk CellsMedicineT-regulatory Cell	2005	299
Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing Mohindar Murugesh Karunakaran, Carrie R. Willcox, Mahboob Salim, Immunity Molecular ImmunologyVγ9vδ2 TcrSignal TransductionNatural SciencesReceptor (Biochemistry)	2020	242

Page 1